NCT03576859: Pyro-TH

Pyrophosphate Homeostasis and Hepatic Expression of ABCC6.Pyro-TH

Completed NA Last updated 24 March 2026

What this trial tests

NA trial testing blood sample in Hepatic Failure in 38 participants. Completed in 29 October 2020.

Timeline

6 November 2018

Primary endpoint
29 October 2020

29 October 2020

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nice
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	38
Start date	6 November 2018
Primary completion	29 October 2020
Estimated completion	29 October 2020
Sites	1 location across France

Drugs / interventions tested

• blood sample — full drug profile →

Conditions studied

• Hepatic Failure — all drugs for Hepatic Failure →

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

18 and older, any sex, with Hepatic Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In animals, normal hepatic expression of ABCC6 (ATP-binding transporter cassette, subfamily C, member 6) determines plasma pyrophosphate (PPi) concentration. PPi prevents the formation of hydroxyapatite crystals on tissues by precipitation of calcium and inorganic phosphate (Pi). It is an endogenous compound whose deficiency causes diffuse vascular calcifications in certain rare monogenic diseases, including the elastic pseudoxanthoma caused by the mutation of ABCC6. PPi is produced by enzymatic transformation of extracellular ATP and, in animals, the liver is the main supplier of ATP and PPi (more than 90%). In humans, liver transplantation offers the possibility of correlating the plasma concentration of PPi (\[PPi\]pl) with hepatic expression of ABCC6. Liver transplantation is performed in the treatment of chronic liver failure (Child B or C) or, in the absence of liver failure, in the treatment of hepatocellular carcinoma. By measuring\[PPi\]pl before transplantation and after liver function restoration and by measuring ABCC6 in the diseased liver and healthy liver, it is possible to determine whether liver failure is associated with decreased\[PPi\]pl and decreased liver expression of ABCC6, which is the objective of our pilot study. Its interest is to establish a physiopathological link between the frequent vascular calcifications in obese patients with hepatic steatosis and the production of PPi.

prupose: Look for a deficit in\[PPi\]pl in patients before the transplant compared to the phase of restoration of liver function

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation.
   Laurain A, Rubera I, Razzouk-Cadet M, Bonnafous S, et al · · 2022 · cited 8× · PMID 35884801 · DOI 10.3390/biomedicines10071496